Mathijssen RHJ - Search Results

1

The added value of H₂ antagonists in premedication regimens during paclitaxel treatment.

Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PMLA, Boere IA, Jager A, Mathijssen RHJ, van Leeuwen RWF. Cox JM, et al. Among authors: mathijssen rhj. Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.

2

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Mathijssen RH, Verweij J, Loos WJ, de Bruijn P, Nooter K, Sparreboom A. Mathijssen RH, et al. Br J Cancer. 2002 Jul 15;87(2):144-50. doi: 10.1038/sj.bjc.6600447. Br J Cancer. 2002. PMID: 12107833 Free PMC article.

3

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

Sparreboom A, Kehrer DF, Mathijssen RH, Xie R, de Jonge MJ, de Bruijn P, Planting AS, Eskens FA, Verheij C, de Heus G, Klaren A, Zhang S, Verhaeghe T, Palmer PA, Verweij J. Sparreboom A, et al. Br J Cancer. 2004 Apr 19;90(8):1508-15. doi: 10.1038/sj.bjc.6601732. Br J Cancer. 2004. PMID: 15083177 Free PMC article. Clinical Trial.

4

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.

Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. Lammers LA, et al. Br J Cancer. 2010 Sep 7;103(6):765-71. doi: 10.1038/sj.bjc.6605800. Epub 2010 Aug 10. Br J Cancer. 2010. PMID: 20700120 Free PMC article.

5

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.

van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. van Doorn L, et al. Thyroid. 2011 Feb;21(2):197-202. doi: 10.1089/thy.2010.0234. Thyroid. 2011. PMID: 21275767

6

Environmental and genetic factors affecting transport of imatinib by OATP1A2.

Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, Gurney H, Kim RB, Tirona RG, Mathijssen RH, Sparreboom A. Eechoute K, et al. Clin Pharmacol Ther. 2011 Jun;89(6):816-20. doi: 10.1038/clpt.2011.42. Epub 2011 Apr 20. Clin Pharmacol Ther. 2011. PMID: 21508937 Free PMC article.

7

Effects of CYP induction by rifampicin on tamoxifen exposure.

Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH. Binkhorst L, et al. Clin Pharmacol Ther. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372. Epub 2012 May 23. Clin Pharmacol Ther. 2012. PMID: 22617226 Clinical Trial.

8

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.

de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH. de Graan AJ, et al. Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645049

9

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs.

van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG. van Leeuwen RW, et al. Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14. Br J Cancer. 2013. PMID: 23412102 Free PMC article.

10

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T. Binkhorst L, et al. Breast Cancer Res Treat. 2013 Jun;139(3):923-9. doi: 10.1007/s10549-013-2585-z. Epub 2013 Jun 13. Breast Cancer Res Treat. 2013. PMID: 23760858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

400 results

Search Page